About Synergy Pharmaceuticals (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020
Debt
Debt-to-Equity Ratio-21.05%
Current Ratio4.33%
Quick Ratio3.88%
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-3.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.82 million
Price / Sales25.66
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-87.50
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-1,333.76%
Return on Equity-652.66%
Return on Assets-157.15%
Miscellaneous
Employees313
Outstanding Shares246,660,000
Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions
What is Synergy Pharmaceuticals' stock symbol?
Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."
How were Synergy Pharmaceuticals' earnings last quarter?
Synergy Pharmaceuticals (NASDAQ:SGYP) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company had revenue of $9.40 million for the quarter, compared to analysts' expectations of $7.12 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 1,333.76%. The business's quarterly revenue was up 840.0% on a year-over-year basis. View Synergy Pharmaceuticals' Earnings History.
What price target have analysts set for SGYP?
8 analysts have issued 12 month target prices for Synergy Pharmaceuticals' shares. Their forecasts range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $8.8125 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.
What are Wall Street analysts saying about Synergy Pharmaceuticals stock?
Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (3/1/2018)
- 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)
Are investors shorting Synergy Pharmaceuticals?
Synergy Pharmaceuticals saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 60,391,166 shares, an increase of 2.4% from the March 15th total of 61,879,187 shares. Based on an average trading volume of 4,169,422 shares, the short-interest ratio is currently 14.5 days. Approximately 24.5% of the shares of the company are short sold.
Who are some of Synergy Pharmaceuticals' key competitors?
Some companies that are related to Synergy Pharmaceuticals include Amarin (AMRN), ARMO BioSciences (ARMO), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), OptiNose (OPTN), Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI) and Rocket Pharmaceuticals (RCKT).
Who are Synergy Pharmaceuticals' key executives?
Synergy Pharmaceuticals' management team includes the folowing people:
- Gary S. Jacob Ph.D., Executive Chairman of the Board (Age 70)
- Troy Hamilton, Chief Executive Officer, Director (Age 45)
- Gary G. Gemignani, Chief Financial Officer, Executive Vice President (Age 52)
- Marino Garcia, Executive Vice President, Chief Strategy Officer (Age 50)
- Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer (Age 61)
- Melvin K. Spigelman M.D., Lead Independent Director (Age 68)
- Thomas H. Adams Jr. Ph.D., Independent Director (Age 74)
- John P. Brancaccio CPA, Independent Director (Age 69)
- Timothy S. Callahan, Independent Director (Age 46)
- Richard J. Daly, Independent Director (Age 56)
Has Synergy Pharmaceuticals been receiving favorable news coverage?
Media headlines about SGYP stock have been trending somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a daily sentiment score of -0.06 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Synergy Pharmaceuticals?
Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synergy Pharmaceuticals' stock price today?
One share of SGYP stock can currently be purchased for approximately $1.75.
How big of a company is Synergy Pharmaceuticals?
Synergy Pharmaceuticals has a market capitalization of $431.65 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.
How can I contact Synergy Pharmaceuticals?
Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]
MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Synergy Pharmaceuticals (NASDAQ:SGYP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Synergy Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8125, suggesting that the stock has a possible upside of 403.57%. The high price target for SGYP is $15.00 and the low price target for SGYP is $2.50. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.63 | 2.63 | 2.67 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.8125 | $8.8125 | $8.9444 | $8.90 |
| Price Target Upside: | 403.57% upside | 361.39% upside | 272.69% upside | 193.73% upside |
Synergy Pharmaceuticals (NASDAQ:SGYP) Consensus Price Target History
Synergy Pharmaceuticals (NASDAQ:SGYP) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Synergy Pharmaceuticals (NASDAQ:SGYP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 53.08%
Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/10/2017 | Paulson & Co. Inc. | Major Shareholder | Sell | 8,750,000 | $2.82 | $24,675,000.00 | |  |
| 8/7/2017 | Paulson & Co. Inc. | Major Shareholder | Sell | 26,287 | $3.77 | $99,101.99 | | |
| 5/26/2017 | Gary S Jacob | CEO | Buy | 5,680 | $3.52 | $19,993.60 | 402,679 | |
| 5/26/2017 | John P Brancaccio | Director | Buy | 6,500 | $3.59 | $23,335.00 | 30,444 | |
| 11/4/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 140,000 | $4.24 | $593,600.00 | | |
| 9/28/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 54,300 | $5.69 | $308,967.00 | | |
| 9/19/2016 | John P Brancaccio | Director | Sell | 2,518 | $5.76 | $14,503.68 | 21,883 | |
| 9/19/2016 | Paulson & Co. Inc. | Major Shareholder | Sell | 3,473,713 | $5.61 | $19,487,529.93 | | |
| 9/14/2015 | Bernard Denoyer | SVP | Sell | 10,000 | $7.50 | $75,000.00 | | |
| 9/11/2015 | Alan Joslyn | Director | Sell | 13,754 | $7.22 | $99,303.88 | | |
| 6/3/2014 | John P Brancaccio | Director | Buy | 3,500 | $4.12 | $14,420.00 | | |
| 5/27/2014 | Gary S Jacob | CEO | Buy | 4,000 | $4.18 | $16,720.00 | | |
| 5/23/2014 | Bernard Denoyer | SVP | Buy | 2,500 | $3.89 | $9,725.00 | | |
| 5/23/2014 | Kunwar Shailubhai | Insider | Buy | 3,000 | $3.89 | $11,670.00 | | |
| 10/29/2013 | Gabriel Cerrone | Director | Buy | 12,000 | $4.09 | $49,080.00 | | |
| 6/21/2013 | Bernard Denoyer | SVP | Buy | 7,500 | $4.78 | $35,850.00 | | |
| 6/14/2013 | Gabriel Cerrone | Chairman | Buy | 8,000 | $4.42 | $35,360.00 | | |
| 4/24/2013 | Gabriel Cerrone | Chairman | Buy | 5,500 | $4.66 | $25,630.00 | | |
| 2/5/2013 | Gabriel Cerrone | Chairman | Buy | 5,000 | $6.15 | $30,750.00 | | |
| 2/4/2013 | Gabriel Cerrone | Chairman | Buy | 13,090 | $6.04 | $79,063.60 | | |
| 1/30/2013 | Gabriel Cerrone | Chairman | Buy | 26,000 | $5.98 | $155,480.00 | | |
| 11/14/2012 | Gabriel Cerrone | Chairman | Buy | 87,820 | $3.61 | $317,030.20 | | |
(Data available from 1/1/2013 forward)
Synergy Pharmaceuticals (NASDAQ SGYP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Synergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - April 20 at 4:17 PM |
 | Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock
finance.yahoo.com - April 18 at 9:35 AM |
| Synergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM |
| -$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM |
| Synergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:37 AM |
| Synergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 6:19 PM |
| Synergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 6:13 PM |
| Synergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 11 at 1:27 PM |
| HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price Target
www.americanbankingnews.com - April 11 at 12:11 AM |
| SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM |
| FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM |
| Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)
finance.yahoo.com - April 10 at 4:40 PM |
| DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:40 PM |
 | Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...
www.businesswire.com - April 10 at 9:29 AM |
| EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...
www.businesswire.com - April 10 at 9:29 AM |
| FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm
finance.yahoo.com - April 9 at 4:43 PM |
| DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 7 at 4:57 PM |
| Synergy Pharmaceuticals (SGYP) Given a $6.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 7 at 12:36 PM |
| Synergy Pharmaceuticals (SGYP) Given a $8.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 6 at 3:32 PM |
| Synergy Pharmaceuticals Inc. Reminder: Important April 10, 2018 Lead Plaintiff Deadline in Class Action– SGYP
finance.yahoo.com - April 6 at 9:30 AM |
 | Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and Perrigo
www.bizjournals.com - April 5 at 4:40 PM |
| 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 5 at 4:40 PM |
| Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder For Synergy Pharmaceuticals Inc. Shareholders - SGYP
finance.yahoo.com - April 5 at 4:40 PM |
| SGYP UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 5 at 4:40 PM |
 | Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and ...
www.prnewswire.com - April 5 at 9:17 AM |
| DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Synergy Pharmaceuticals, Inc. (SGYP) and Encourages Investors to Contact the Firm Before April 10th
finance.yahoo.com - April 4 at 4:50 PM |
| 7-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 3 at 4:40 PM |
| The Klein Law Firm Reminds Investors of Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 3 at 4:40 PM |
| FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Synergy Pharmaceuticals Inc. to Contact the Firm
finance.yahoo.com - April 1 at 9:19 AM |
| Synergy Pharmaceuticals (SGYP) Expected to Post Quarterly Sales of $12.20 Million
www.americanbankingnews.com - April 1 at 4:02 AM |
| 3 Favorite Biotech Stocks for the Second Quarter
finance.yahoo.com - March 31 at 4:39 PM |
| IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - March 30 at 4:46 PM |
| Synergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 30 at 1:14 PM |
| Zacks: Analysts Expect Synergy Pharmaceuticals (SGYP) to Post -$0.16 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:23 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 29 at 4:40 PM |
| APRIL 10 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - March 29 at 9:32 AM |
| The Klein Law Firm Reminds Investors of the Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 28 at 4:38 PM |
| Synergy Pharmaceuticals (SGYP) Lifted to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 10:58 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Commencement of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 26 at 4:49 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - March 26 at 4:49 PM |
| Synergy Pharmaceuticals Inc (NASDAQ:SGYP): Is Breakeven Near?
finance.yahoo.com - March 23 at 6:15 PM |
| Synergy Pharmaceuticals (SGYP) Receives "Hold" Rating from Oppenheimer
www.americanbankingnews.com - March 23 at 6:06 PM |
| SGYP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 22 at 4:53 PM |
 | Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Synergy Pharmaceuticals Inc. Shareholders – SGYP
feeds.benzinga.com - March 22 at 8:37 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 21 at 4:58 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) and Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - March 21 at 4:58 PM |
| The Klein Law Firm Reminds Investors of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 20 at 4:49 PM |
| DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm
finance.yahoo.com - March 20 at 9:14 AM |
| Synergy Pharmaceuticals Inc (SGYP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM |
| SYNERGY PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.
finance.yahoo.com - March 16 at 4:52 PM |
Synergy Pharmaceuticals (NASDAQ:SGYP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Synergy Pharmaceuticals (NASDAQ:SGYP) Income Statement, Balance Sheet and Cash Flow Statement
Synergy Pharmaceuticals (NASDAQ SGYP) Stock Chart for Monday, April, 23, 2018
Loading chart…
